$PLRX

Pliant Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Medicinal and Botanical Manufacturing

PRICE

$14.15 β–Ό-0.212%

Delayed Price

VOLUME

165,872

DAY RANGE

- 14.25

52 WEEK

12.61 - 36.64

Join Discuss about PLRX with like-minded investors

profile
@dros #droscrew
recently

Upgrades 4/13: $BX $CFRX $CVX $DKNG $EOG $INGR $MNTK $MRK $NVO $SHOO $SPWR $VFC $WWE .. Downgrades 4/13: $BRFS $CUBE $FSLR $JD $LSI $LXU $LYB $NATI $NSA $PKX $PLTK $SPWH $TESS $TRTN $XOM +Initiations 4/13: $AVGO $CCCS $COST $CRSP $ENPH $FTCI $MGNI $NTLA $PLRX $PRI $PUBM $RLAY $RXST $SEDG $SNAL $VERV .. -Initiations 4/13:

136 Replies 13 πŸ‘ 13 πŸ”₯

profile
@singletary #StockTraders.NET
recently

πŸ‘€ usual main chicks then $brpm $clnn $goev $goss $th $rytm $plrx $evgo $ffie $ormp $ysg

61 Replies 12 πŸ‘ 9 πŸ”₯

profile
@singletary #StockTraders.NET
recently

$plrx 21.3 was of interest few days ago, will watch tomorrow

150 Replies 12 πŸ‘ 7 πŸ”₯

profile
@singletary #StockTraders.NET
recently

πŸ‘€ $mrna $nvax $ormp $plrx $kspn $veru $amc

144 Replies 10 πŸ‘ 14 πŸ”₯

SO
@soheil.n #StockTraders.NET
recently

got chopped up that i missed the high level plan for HOD clear out > @soheil.n said: $PLRX - gotten chopped on it few times...only to cover for it to run the other way

135 Replies 6 πŸ‘ 8 πŸ”₯

SO
@soheil.n #StockTraders.NET
recently

$PLRX - gotten chopped on it few times...only to cover for it to run the other way

92 Replies 13 πŸ‘ 6 πŸ”₯

SO
@soheil.n #StockTraders.NET
recently

$PLRX - attempted long again

46 Replies 6 πŸ‘ 6 πŸ”₯

SO
@soheil.n #StockTraders.NET
recently

small long $PLRX

129 Replies 11 πŸ‘ 7 πŸ”₯

profile
@dros #droscrew
recently

Upgrades 11/24: $AEG $CVX $DEO $DLTR $FMX $GRUB $SYBX $YSG .. Downgrades 11/24: $BABA $BBY $GPS $HTA $JACK $JWN $NOAH $PLAN $RPM $TITN +Initiations 11/24: $AURA $AVY $BFRI $BTTX $CFG $DSEY $GPK $LIAN $MYNA $OCUP $PLRX $SLGN $SPAQ $SPOT $TRDA .. -Initiations 11/24:

73 Replies 11 πŸ‘ 7 πŸ”₯

Key Metrics

Market Cap

849.32 M

Beta

0.80

Avg. Volume

454.14 K

Shares Outstanding

59.90 M

Yield

0%

Public Float

0

Next Earnings Date

2024-03-07

Next Dividend Date

Company Information

pliant therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. by harnessing the therapeutic potential of integrin biology and tgf-Ξ² modulation, pliant aims to prevent or even reverse fibrosis to address the needs of many patients. the company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. pliant’s co-founders include world-renowned researchers from university of california, san francisco (ucsf), who bring broad experience in fibrosis biology and small molecule chemistry. together, the pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.

CEO: Bernard Coulie

Website:

HQ: 260 Littlefield Avenue South San Francisco, 94080 California

Related News